Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

Fig. 3

Physical well-being, hair loss, numbness, treatment burden, mood and coping effort. Data are means with 95 % CIs from baseline over 12 treatment cycles with the number of patients for each cycle. Higher scores indicate better condition. The continuous lines indicate the standard arm (a), the dashed lines the experimental arm (b)

Back to article page